$NUVL

Squarer Ron sold (to issuer) 6,281 shares of NUVL

Squarer Ron sold (to issuer) 6,281 shares of Nuvalent, Inc. (NUVL) on 2026-07-15.

Original reporting
SEC EDGAR · Squarer Ron
Published Jul 15, 2026, 11:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 11:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NUVL
Neutral
low confidence
Mentioned
$NUVL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVLNeutralLow
01

Why it matters

The disclosure provides incremental information about director-level share activity but does not include financial results, guidance, or a corporate action that would directly reset valuation.

02

Market read

Traders may monitor insider activity for sentiment, but the lack of disclosed price/value and absence of other catalysts makes this more of a background datapoint than a decision driver.

03

What to watch

No 10b5-1 plan is cited, but the price and total value are not disclosed, limiting inference about motivation or materiality.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed July 15, after-hours (19:03:13-04:00)

Background

The article is an SEC Form 4 insider transaction disclosure for Nuvalent, Inc.

Company-level read

Ticker impact

$NUVLNeutralLow confidence
Context

Nuvalent director Squarer Ron sold 6,281 shares to the issuer in an SEC Form 4 filed July 15, with price undisclosed.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction, but the transaction value is not disclosed and the size is small relative to typical company float, with no accompanying corporate event described.

Market effects

No sector read-across; this is company-specific insider trading with no operational or regulatory linkage.

None indicated.

None indicated.

Counterpoint

The sale is coded as D (sale to issuer) and may reflect planned liquidity or buyback participation rather than a bearish view.

Key entities

  • Nuvalent, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Squarer Ron

    Director who sold 6,281 shares to the issuer (price not disclosed).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.